



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office

*CORRESPONDENCE
Frontiers Production Office,
production.office@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

RECEIVED 30 September 2022
ACCEPTED 30 September 2022
PUBLISHED 20 October 2022

CITATION
Frontiers Production Office (2022),
Erratum: Case report: PTEN mutation
induced by anti-PD-1 therapy in stage IV
lung adenocarcinoma.
Front. Pharmacol. 13:1058178.
doi: 10.3389/fphar.2022.1058178

COPYRIGHT
© 2022 Frontiers Production Office.
This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Erratum: Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma

Frontiers Production Office*

KEYWORDS

ErbB2 mutation, afatinib, adenocarcinoma cell lung carcinoma, PTEN mutation, immunotherapy

An Erratum on

Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma

by Teng, J., Zhou, K., Lv, D., Wu, C., and Feng, H. (2022). *Front. Pharmacol.* 13:714408. doi: 10.3389/fphar.2022.714408

Due to a production error, the author affiliations were listed incorrectly, as “Junjie Teng^{1,2,†}, Kai Zhou^{2,†}, Dongxiao Lv², Changshun Wu^{3,*} and Hong Feng^{2,*}” instead of “Junjie Teng^{1,2,†}, Kai Zhou^{1,†}, Dongxiao Lv¹, Changshun Wu^{3,*} and Hong Feng^{1,*}”.

The publisher apologizes for this mistake. The original version of this article has been updated.